Study finds significant differences in who receives anti-amyloid therapy, but not in adherence once treatment begins ...

(fotostorm/E+/Getty Images) A significant amount of Alzheimer's research is looking at ways to tackle the harmful clumps of ...

"Exciting and highly promising": Researcher hopes newly discovered peptide could halt Alzheimer's progression.

The most influential change has been the evolution of biomarkers, beginning around 2012 with the approval of amyloid PET, so ...

Agitation associated dementia is one of the most common symptoms of Alzheimer's disease.

A study suggests that a surprisingly modest daily walking goal could make a difference for your brain as you age.

Learn how Alzheimer's disease is diagnosed through history, testing, imaging, and emerging blood biomarkers to support early ...

Walk to End Alzheimer’s events across the country are bringing together people affected by the disease, caregivers and ...

Award to Dr. Walter Swardfager, from Sunnybrook Research Institute, will support a proof-of-mechanism clinical trial ...

The AD-SMART trial tests repurposed drugs like metformin and atomoxetine in a hopeful, faster approach to Alzheimer’s care.

Diagnosed with Alzheimer's at 59; an Erwin woman is turning her personal journey into advocacy as she prepares to walk in ...

The Alzheimer's disease competitive landscape report delivers important insights into approved as well as ongoing research on 240+ pipeline Alzheimer's disease drugs, clinical strategies, upcoming ...